$GLUE

Manning Anthony M. sold $231K of GLUE

Manning Anthony M. sold 10,000 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.11 ($0.23M total) on 2026-06-29.

Original reporting
SEC EDGAR · Manning Anthony M.
Published Jun 30, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GLUE
Neutral
low confidence
Mentioned
$GLUE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUENeutralLow
01

Why it matters

A director’s open-market sale of 10,000 shares at $23.11 is new information, but it does not include any accompanying company-specific news (earnings, trial results, guidance, or regulatory action).

02

Market read

Traders may monitor for follow-on insider activity or confirm whether the sale aligns with broader ownership trends, but the text alone is unlikely to drive a major repricing.

03

What to watch

The filing does not disclose motivations, tax events, or whether other insiders/large holders are changing positions; traders should avoid over-weighting a single sale.

Relevance 4/10Novelty 5/10Timing: after-hours/filing date (2026-06-30) for a 2026-06-29 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Monte Rosa Therapeutics, Inc. (GLUE).

Company-level read

Ticker impact

$GLUENeutralLow confidence
Context

SEC Form 4 shows director Manning Anthony sold 10,000 shares of Monte Rosa Therapeutics at $23.11 on 2026-06-29, leaving 0 shares.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless accompanied by other news.

Evidence & confidence

This is a routine Form 4 transaction with no 10b5-1 plan stated and no accompanying operational/regulatory update in the text.

Market effects

No sector read-through provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for diversification or liquidity needs; without a stated 10b5-1 plan, the sale still may not signal negative fundamentals.

Key entities

  • Monte Rosa Therapeutics, Inc.

    Subject of the Form 4 insider transaction; director sold 10,000 shares at $23.11.

  • Manning Anthony M.

    Director who executed the open-market sale disclosed on Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GLUEMed

Monte Rosa Therapeutics assumed with a Buy at UBS

UBS initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $19 price target, citing the potential of its drug MRT-8102 for chronic inflammatory diseases. The firm highlights the drug's differentiated profile and the company's atherosclerotic cardiovascular disease opportunity.

$GLUEMedAI 8/10

H.C. Wainwright reiterates Monte Rosa stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (GLUE) after positive clinical trial results for MRT-8102. The stock is currently trading at $10.50, down 10% over the past week. Jefferies also raised its price target to $40, maintaining a Buy rating. The company is conducting a phase 2 study for metastatic prostate cancer and expects further clinical data catalysts in 2026 and 2027.

$GLUEMedAI 8/10

Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win

Monte Rosa Therapeutics reported positive Phase 1 results for MRT-8102, showing significant biomarker reductions and no serious adverse events. The data supports its planned Phase 2b study in coronary artery disease. The company forecasts revenue of $88.1M and earnings of $15.2M by 2029, with current losses of $161.1M and revenue of $28.7M.

$GLUEMedAI 8/10

Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1

Monte Rosa Therapeutics (GLUE) reported Phase 1 results showing MRT-8102 achieved 80%-90% NEK7 degradation, reducing biomarkers linked to cardiovascular disease. The treatment was well-tolerated with no serious adverse events. GLUE plans Phase 2 trials in 2026-2027 for coronary artery disease, gout, and hidradenitis suppurativa. GLUE stock is currently down 5.74% at $11.24.